Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1080/14756366.2020.1850710

http://scihub22266oqcxt.onion/10.1080/14756366.2020.1850710
suck pdf from google scholar
33430659!7808739!33430659
unlimited free pdf from europmc33430659    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33430659      J+Enzyme+Inhib+Med+Chem 2021 ; 36 (1): 147-153
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors #MMPMID33430659
  • Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
  • J Enzyme Inhib Med Chem 2021[Dec]; 36 (1): 147-153 PMID33430659show ga
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID-19). Since its emergence, the COVID-19 pandemic has not only distressed medical services but also caused economic upheavals, marking urgent the need for effective therapeutics. The experience of combating SARS-CoV and MERS-CoV has shown that inhibiting the 3-chymotrypsin-like protease (3CLpro) blocks the replication of the virus. Given the well-studied properties of FDA-approved drugs, identification of SARS-CoV-2 3CLpro inhibitors in an FDA-approved drug library would be of great therapeutic value. Here, we screened a library consisting of 774 FDA-approved drugs for potent SARS-CoV-2 3CLpro inhibitors, using an intramolecularly quenched fluorescence (IQF) peptide substrate. Ethacrynic acid, naproxen, allopurinol, butenafine hydrochloride, raloxifene hydrochloride, tranylcypromine hydrochloride, and saquinavir mesylate have been found to block the proteolytic activity of SARS-CoV-2 3CLpro. The inhibitory activity of these repurposing drugs against SARS-CoV-2 3CLpro highlights their therapeutic potential for treating COVID-19 and other Betacoronavirus infections.
  • |*COVID-19 Drug Treatment[MESH]
  • |*Drug Repositioning[MESH]
  • |Antiviral Agents/*pharmacology[MESH]
  • |COVID-19/*virology[MESH]
  • |Catalytic Domain[MESH]
  • |Coronavirus 3C Proteases/*antagonists & inhibitors/chemistry[MESH]
  • |Cysteine Proteinase Inhibitors/*pharmacology[MESH]
  • |Drug Evaluation, Preclinical[MESH]
  • |Fluorescent Dyes[MESH]
  • |Humans[MESH]
  • |Molecular Docking Simulation[MESH]
  • |SARS-CoV-2/*drug effects/*enzymology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box